Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exagen (XGN) Liabilities and Shareholders Equity (2018 - 2025)

Exagen's Liabilities and Shareholders Equity history spans 8 years, with the latest figure at $58.0 million for Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity rose 29.84% year-over-year to $58.0 million; the TTM value through Dec 2025 reached $219.9 million, up 16.71%, while the annual FY2025 figure was $58.0 million, 29.84% up from the prior year.
  • Liabilities and Shareholders Equity reached $58.0 million in Q4 2025 per XGN's latest filing, down from $62.8 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $137.5 million in Q1 2021 to a low of $40.3 million in Q1 2025.
  • Average Liabilities and Shareholders Equity over 5 years is $80.4 million, with a median of $63.5 million recorded in 2023.
  • Peak YoY movement for Liabilities and Shareholders Equity: soared 65.59% in 2021, then tumbled 40.03% in 2023.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $123.4 million in 2021, then plummeted by 30.15% to $86.2 million in 2022, then tumbled by 33.96% to $56.9 million in 2023, then fell by 21.52% to $44.7 million in 2024, then grew by 29.84% to $58.0 million in 2025.
  • Per Business Quant, the three most recent readings for XGN's Liabilities and Shareholders Equity are $58.0 million (Q4 2025), $62.8 million (Q3 2025), and $58.8 million (Q2 2025).